| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/09/2009 | WO2009006089A3 A2 adenosine receptor agonists |
| 04/09/2009 | WO2009005551A3 Transcription factor modulating compounds and methods of use thereof |
| 04/09/2009 | WO2009004999A8 Seamless capsule |
| 04/09/2009 | WO2009003868A3 2 -imidazolines having a good affinity to the trace amine associated receptors (taars) |
| 04/09/2009 | WO2009003595A3 Macrolactone derivatives |
| 04/09/2009 | WO2008156645A3 Pharmaceutical compositions and uses |
| 04/09/2009 | WO2008155670A3 Arylamide pyrimidone compounds |
| 04/09/2009 | WO2008155666A3 Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases |
| 04/09/2009 | WO2008155534A3 Neurosteroid compounds |
| 04/09/2009 | WO2008154482A3 Sirna compositions and methods of use in treatment of ocular diseases |
| 04/09/2009 | WO2008152099A3 Aryl/hetarylamides as modulators of the ep2 receptor |
| 04/09/2009 | WO2008152093A3 Diaminopyrimidines as modulators of the ep2 receptor |
| 04/09/2009 | WO2008151927A3 6-n-substituted benz imidazole derivatives as acid pump antagonists |
| 04/09/2009 | WO2008149163A3 Potassium ion channel modulators and uses thereof |
| 04/09/2009 | WO2008148879A3 Use of a substance to improve postoperative outcome after end-to-end reconstruction of peripheral nerves |
| 04/09/2009 | WO2008148867A3 Quinoxaline derivatives as inhibitors of the tyrosine kinase activity of janus kinases |
| 04/09/2009 | WO2008148710A3 Aryloxazole, aryloxadiazole and benzimidazole derivatives as modulators of somatostatins receptor activity |
| 04/09/2009 | WO2008147483A9 Neurogenic compounds |
| 04/09/2009 | WO2008138943A3 Prophylactic and therapeutic use of sirtuin inhibitors in tnf-alpha mediated pathologies |
| 04/09/2009 | WO2008138904A3 Rna antagonist compounds for the modulation of her3 |
| 04/09/2009 | WO2008137923A3 Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders |
| 04/09/2009 | WO2008137126A3 Combination therapy for the treatment of hcv infection |
| 04/09/2009 | WO2008121592A3 Acetyl coenzyme a carboxylase inhibitors |
| 04/09/2009 | WO2008114800A8 Solid preparation comprising 2- [ [6- [ (3r) -3-amino-1-piperidinyl] -3, 4-dihydro-3-methyl-2, 4-dioxo-1 (2h) -pyrimidinyl] methyl] -4-fluorobenzonitrile |
| 04/09/2009 | WO2008112124A3 Orally administrable films |
| 04/09/2009 | WO2008107724A3 Stabilisation of biological cell markers |
| 04/09/2009 | WO2008107533A3 Association of compounds inhibiting melanogenesis and use thereof in cosmetics and dermatology |
| 04/09/2009 | WO2008083302A3 Use of adenosine deaminase for treating pulmonary disease |
| 04/09/2009 | WO2008077591A3 Pharmaceutical formulation comprising neurokinin antagonist |
| 04/09/2009 | WO2008076351A3 Dissolution of amyloid fibrils by flavonoids and other compounds |
| 04/09/2009 | WO2008075369A3 T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery |
| 04/09/2009 | WO2008074997A8 Pyridine benzamides and pyrazine benzamides used as pkd inhibitors |
| 04/09/2009 | WO2008073623A3 Soluble epoxide hydrolase inhibitors |
| 04/09/2009 | WO2008070666A3 Compositions and methods to treat cancer with cpg rich dna and cupredoxins |
| 04/09/2009 | WO2008070557A3 Organometallic complexes as therapeutic agents |
| 04/09/2009 | WO2008067909A3 Urea and sulfamide derivatives as tafia inhibitors |
| 04/09/2009 | WO2008063760A3 Methods for treating cancer targeting transglutaminase |
| 04/09/2009 | WO2008060535A3 Use of reversine and analogs for treatment of cancer |
| 04/09/2009 | WO2008058357A3 Descriptive report of patent of invention of the medicament candesartana + metformin in combined form for cardiovascular diseases |
| 04/09/2009 | WO2008058356A3 Descriptive report of patent of invention of the hemodiluted stent with the medicament metformin for prevention of intracoronary reestenose |
| 04/09/2009 | WO2008058285A3 4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors |
| 04/09/2009 | WO2008057543A3 Uii-modulating compounds and their use |
| 04/09/2009 | WO2008054215A3 Use of 3-alpha-androstanediol, optionally in combination with a 5-ht1a agonist, in the treatment of sexual dysfunction |
| 04/09/2009 | WO2008054214A3 Use of 3-alpha-androstanediol, optionally in combination with a pde5 inhibitor, in the treatment of sexual dysfunction |
| 04/09/2009 | WO2008054213A3 Use of testosterone and a 5-ht1a agonist in the treatment of sexual dysfunction |
| 04/09/2009 | WO2008051197A3 Small-molecule botulinum toxin inhibitors |
| 04/09/2009 | WO2008050168A8 New sulfonamide derivatives as bradykinin antagonists |
| 04/09/2009 | WO2008049000A3 Combination therapy for pulmonary arterial hypertension |
| 04/09/2009 | WO2008048685A3 Ox40 aptamers |
| 04/09/2009 | WO2008025025A3 Antisense composition and method for inhibition of mirna biogenesis |
| 04/09/2009 | WO2008024509A3 Cationic latex as a carrier for bioactive ingredients and methods for making and using the same |
| 04/09/2009 | WO2008023266A3 Kiwi extract |
| 04/09/2009 | WO2008022365A3 Compositions for influencing the effects of organophosphorus compounds and use of galanthamine, its derivatives and analogues for producing such compositions |
| 04/09/2009 | WO2008016676A3 Certain chemical entities, compositions, and methods |
| 04/09/2009 | WO2008006085A3 Compositions and methods for predicting inhibitors of protein targets |
| 04/09/2009 | WO2008005802A3 Nasal formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| 04/09/2009 | WO2008004224A3 Synergistic compositions for crohn's disease and inflammatory gastrointestinal disorders |
| 04/09/2009 | WO2007149493A3 Restoration of hearing loss |
| 04/09/2009 | WO2007134014A3 Compounds and methods for modulating expression of gcgr |
| 04/09/2009 | WO2007124423A3 Il-8 receptor antagonists |
| 04/09/2009 | WO2007123732A3 Antifungal and antiparasitic indoloquinoline derivatives |
| 04/09/2009 | WO2007120484A3 Use of inositol-tripyrophosphate in treating tumors and diseases |
| 04/09/2009 | WO2007118143A3 Process for the isolation of limonoid glucosides from citrus |
| 04/09/2009 | WO2007110861A3 Apparatus and method for feeding chicks during the hatching process |
| 04/09/2009 | WO2007091253A3 Pharmaceutical compositions comprising clopidogrel and vitamins which reduce homocysteine levels |
| 04/09/2009 | WO2007089336A3 Certain chemical entities, compositions and methods |
| 04/09/2009 | WO2007086895A3 Antibacterial compounds and uses thereof |
| 04/09/2009 | WO2007075269A3 Method for inhibiting tooth displacement with non-antibacterial tetracyline formulations |
| 04/09/2009 | WO2007038623A3 Oral formulation for enteric disorders and/or rehydration |
| 04/09/2009 | WO2007034511A3 Novel solubility enhancer and use thereof |
| 04/09/2009 | WO2007032009A3 Use of tellurium compounds for treatment of basal cell carcinoma and/or actinic keratosis |
| 04/09/2009 | WO2007005443A3 Therapeutic methods employing pai-1 inhibitors and transgenic non-human animal for screening candidate pai-1 inhibitors |
| 04/09/2009 | WO2007002928A3 Treatment of occlusive thrombosis |
| 04/09/2009 | WO2007002885A3 Compositions and methods for use of a sodium channel blocker |
| 04/09/2009 | WO2007001453A3 Glycerin based synthesis of silver nanoparticles and nanowires |
| 04/09/2009 | WO2007000662A3 Novel propofol composition comprising ascorbic acid or pharmaceutically acceptable salts thereof |
| 04/09/2009 | WO2006134591A3 Use of allylmercaptocaptopril for treating or preventing obesity and obesity related diseases |
| 04/09/2009 | WO2006126981A3 Compositions and methods for mucosal vaccination |
| 04/09/2009 | WO2006124275A3 Low dose administration of a topical composition |
| 04/09/2009 | WO2006107860A3 Dihydropyridine compounds and compositions for headaches |
| 04/09/2009 | WO2006107859A3 Dihydropyridine compounds for neurodegenerative diseases and dementia |
| 04/09/2009 | WO2006094015A3 Method of treating depression, mood disorders and anxiety disorders using neuromodulation |
| 04/09/2009 | WO2006086623A3 Drug composition and method for treating malaria and malignancy |
| 04/09/2009 | WO2006085942A3 Compositions and methods for regulating gene transcription |
| 04/09/2009 | WO2006063111A3 Pharmaceutical formulations cytidine analogs and derivatives |
| 04/09/2009 | WO2006060186A3 Pyrazole derivatives for the treatment of dementia and related disorders |
| 04/09/2009 | WO2006044333A3 Methods and materials for the inhibition of transplant rejection |
| 04/09/2009 | WO2006034039A3 Substituted morphinans and methods of their use |
| 04/09/2009 | WO2006023881A3 T type calcium channel blockers and the treatment of diseases |
| 04/09/2009 | WO2006017491A3 Methods and compositions to reduce tissue irritation in parenteral formulations |
| 04/09/2009 | WO2006017124A3 Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases |
| 04/09/2009 | WO2006014703A3 Homopiperdinine derivatives as nk-1 antagonists |
| 04/09/2009 | WO2006012204A3 Method for treatment of inflammatory disorders using triptolide compounds |
| 04/09/2009 | WO2006007400A9 Methods of diagnosing and treating obesity, diabetes and insulin resistance |
| 04/09/2009 | WO2006007023A3 The ubeg2 binding domain in the ubiquitin ligase gp78 and methods of use thereof |
| 04/09/2009 | WO2006002022A3 Compositions and methods useful for the treatment of hyperglycemia |
| 04/09/2009 | WO2005118876A3 Egfr mutations |
| 04/09/2009 | WO2005117871A3 Pharmaceutical compositions for the treatment of pruritus |
| 04/09/2009 | WO2005115407A3 Calmodulin independent activation of nitric oxide synthase |
| 04/09/2009 | WO2005115395A3 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |